Now Reading: Price cap on 1,366 anti-cancer drugs saves Rs 2,500 crore annually
-
01
Price cap on 1,366 anti-cancer drugs saves Rs 2,500 crore annually
The Story in Brief
India's National Pharmaceutical Pricing Authority (NPPA) has capped trade margins at 30% for 1,366 anti-cancer drug brands, effective 9 November 2026. The move is expected to save cancer patients approximately Rs 2,500 crore annually. The list includes drugs based on 137 chemicals and biologic substances not covered under the Drug Price Control Order.
Indian Opinion Analysis
Economic Times reports the NPPA's price cap as a significant step, citing expected savings of Rs 2,500 crore and the Supreme Court's description of drug pricing as 'loot and carnage'. New Indian Express, through an oncologist interview, notes that while the cap will lower drug costs, lab tests and scans remain a major, recurring expense not covered by the measure. The outlets agree on the policy's implementation but differ in focus: Economic Times highlights the regulatory achievement and court backing, while New Indian Express emphasises the cap's limitations. Patient advocate Working Group on Access to Medicines and Treatments added that prices of 201 of 1,366 brands, including 159 patented drugs, remain unchanged. The Supreme Court has reserved its judgment in the related case.
Coverage: 2 sources, 1 pro-government, 1 neutral
Sources (2): newindianexpress.com (neutral report), economictimes.indiatimes.com (pro government)
This brief was synthesised by AI from the 2 sources linked above, so one read covers every framing they carry. Methodology and corrections.
Update, 10 November 2026: this story now draws on 2 sources.
